We recognized early the importance of direct analysis of protein, since the product of a gene is inherently more complex and closer to function than the gene itself. This insight led to our founding as a biotechnology company.
PROTEINA developed the first-in-class Protein-Protein Interaction (PPI) analysis platform (“Single-Molecule Co-Immunoprecipitation Technology”) that enables quantitative PPI measurement at the single-molecule level. PROTEINA has accumulated extensive know-how in developing assays measuring the targeted PPI as well as the analytic capability to model the efficacy of a drug based on its PPI metrics.
Our mission is to analyze proteins in a new way, developing effective, new approaches to diagnosing disease and discovering new drug candidates, with our novel technology.